234,515 Shares in Agilent Technologies, Inc. $A Purchased by Foresight Group Ltd Liability Partnership

Key Points

• Foresight Group Ltd Liability Partnership invested approximately $27.43 million in Agilent Technologies, acquiring 234,515 shares, which now represents 4.0% of their portfolio.
• Various hedge funds have increased their positions in Agilent Technologies, including Whipplewood Advisors LLC, which raised its stake by 286.2% during the first quarter.
• Agilent Technologies reported a quarterly revenue of $1.74 billion, exceeding analysts' expectations, and set its FY 2025 EPS guidance at $5.560 - $5.590.

Foresight Group Ltd Liability Partnership bought a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 234,515 shares of the medical research company's stock, valued at approximately $27,434,000. Agilent Technologies accounts for about 4.0% of Foresight Group Ltd Liability Partnership's portfolio, making the stock its 9th largest holding. Foresight Group Ltd Liability Partnership owned 0.08% of Agilent Technologies as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in A. Vanguard Group Inc. increased its holdings in shares of Agilent Technologies by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company's stock valued at $3,908,141,000 after buying an additional 240,965 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Agilent Technologies by 2.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock valued at $624,888,000 after acquiring an additional 128,131 shares in the last quarter. Generation Investment Management LLP lifted its stake in shares of Agilent Technologies by 19.8% in the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock valued at $582,976,000 after purchasing an additional 824,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Agilent Technologies by 18.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company's stock valued at $448,748,000 after purchasing an additional 604,124 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Agilent Technologies by 9.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,231,981 shares of the medical research company's stock valued at $434,184,000 after purchasing an additional 283,445 shares during the last quarter. Institutional investors own 87.41% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on A shares. Leerink Partners boosted their target price on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Friday, May 30th. Wells Fargo & Company upped their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Barclays reaffirmed an "equal weight" rating and set a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Wall Street Zen cut shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. Finally, UBS Group cut their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $139.25.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.26% of the company's stock.

Agilent Technologies Stock Performance

Shares of NYSE A traded down $3.54 during mid-day trading on Friday, reaching $123.19. 1,250,804 shares of the company were exchanged, compared to its average volume of 1,689,851. The company's 50-day simple moving average is $119.76 and its 200-day simple moving average is $115.87. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $34.92 billion, a P/E ratio of 28.92, a P/E/G ratio of 3.94 and a beta of 1.24. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting the consensus estimate of $1.37. The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business's revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.